|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human, Mouse|
|Host / Isotype||Mouse / IgG2a|
|Immunogen||Synthetic peptide corresponding to N-terminus of mouse BCL-XL protein|
|Storage buffer||PBS, pH 7.6, with 1% BSA|
|Contains||<0.1% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:400|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody is predicted to react with rat based on sequence homology.
Heat-mediated antigen retrieval is recommended prior to staining, using a 10mM citrate buffer, pH 6.0, for 10 minutes followed by cooling at room temperature for 20 min. Following antigen retrieval, incubate samples with primary antibody for 30 min at room temperature. A suggested positive control is Hodgkin's lymphoma.
Bcl xL is a 241 amino acid 28 kDa member of Bcl2 family of proteins and an important regulator of apoptosis. Bcl xL forms heterodimers with BAX, BAK, and Bcl2, and its overexpression in tumor cells confers resistance against chemotherapeutic drugs. Bcl xL is phosphorylated on many sites including serine 62, a critical site for Bcl xL response to microtubule-damaging drugs such as taxol and vinblastine. Phosphorylation of serine 62 is thought to be mediated by Jun N-terminal stress kinase (JNK) signaling - negatively regulates the anti-apoptotic function of Bcl xL and controls the growth of neoplastic cells.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
New diagnostic markers in salivary gland tumors.
MA1-37166 was used in immunohistochemistry to study the expresion of tumor antigens in order to identify novel diagnostic markers of parotid gland tumors
|Schneider S,Kloimstein P,Pammer J,Brannath W,Grasl MCh,Erovic BM||European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (271:1999)||2014|
Biomarkers in advanced larynx cancer.
MA1-37166 was used in immunohistochemistry to study the predictive and prognostic value of a range of biomarkers in pre-treatment biopsies from patients with advanced cancer of the larynx
|Bradford CR,Kumar B,Bellile E,Lee J,Taylor J,D'Silva N,Cordell K,Kleer C,Kupfer R,Kumar P,Urba S,Worden F,Eisbruch A,Wolf GT,Teknos TN,Prince ME,Chepeha DB,Hogikyan ND,Moyer JS,Carey TE||The Laryngoscope (124:179)||2014|
Identification of novel target proteins in sebaceous gland carcinoma.
MA1-37166 was used in immunohistochemistry to identify novel therapeutic target proteins in sebaceous gland carcinoma
|Erovic BM,Al Habeeb A,Harris L,Goldstein DP,Kim D,Ghazarian D,Irish JC||Head and neck (35:642)||2013|
Head and neck squamous cell carcinoma in pregnant women.
MA1-37166 was used in immunohistochemistry to study oral cancer in pregnant women
|Eliassen AM,Hauff SJ,Tang AL,Thomas DH,McHugh JB,Walline HM,Stoerker J,Maxwell JH,Worden FP,Eisbruch A,Czerwinski MJ,Papagerakis SM,Chepeha DB,Bradford CR,Hanauer DA,Carey TE,Prince ME||Head and neck (35:335)||2013|
Biomarkers of parathyroid carcinoma.
MA1-37166 was used in immunohistochemistry to establish a biomarker panel suitable for the identification of parathyroid carcinomas
|Erovic BM,Harris L,Jamali M,Goldstein DP,Irish JC,Asa SL,Mete O||Endocrine pathology (23:221)||2012|
Radiotherapy in laryngeal carcinoma: can a panel of 13 markers predict response?
MA1-37166 was used in immunohistochemistry to study the value of 13 immunohistochemical biomarkers in predicting response to radiotherapy in laryngeal cancer
|Wildeman MA,Gibcus JH,Hauptmann M,Begg AC,van Velthuysen ML,Hoebers FJ,Mastik MF,Schuuring E,van der Wal JE,van den Brekel MW||The Laryngoscope (119:316)||2009|
Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer.
MA1-37166 was used in immunohistochemistry to examine the prognostic significance of p53 and Bcl-xL as predictive markers in advanced laryngeal cancer
|Kumar B,Cordell KG,D'Silva N,Prince ME,Adams ME,Fisher SG,Wolf GT,Carey TE,Bradford CR||Archives of otolaryngology--head and neck surgery (134:363)||2008|
Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
MA1-37166 was used in immunohistochemistry to investigate the expression of Bcl-xL and p53 in cisplatin-resistant head and neck squamous cell cancers
|Bauer JA,Kumar B,Cordell KG,Prince ME,Tran HH,Wolf GT,Chepeha DB,Teknos TN,Wang S,Eisbruch A,Tsien CI,Urba SG,Worden FP,Lee J,Griffith KA,Taylor JM,D'Silva N,Wang SJ,Wolter KG,Henson B,Fisher SG,Carey TE,Bradford CR||International journal of radiation oncology, biology, physics (69:S106)||2007|
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
MA1-37166 was used in immunohistochemistry to perform a phase I clinical study of oblimersen and irintecan in advanced metastatic colorectal cancer
|Mita MM,Ochoa L,Rowinsky EK,Kuhn J,Schwartz G,Hammond LA,Patnaik A,Yeh IT,Izbicka E,Berg K,Tolcher AW||Annals of oncology : official journal of the European Society for Medical Oncology (17:313)||2006|
Bcl-2 expression predicts radiotherapy failure in laryngeal cancer.
MA1-37166 was used in immunohistochemistry to study the value of Bcl-2 expression in predicting the response to radiotherapy of laryngeal cancer patients
|Nix P,Cawkwell L,Patmore H,Greenman J,Stafford N||British journal of cancer (92:2185)||2005|
MyoD regulates apoptosis of myoblasts through microRNA-mediated down-regulation of Pax3.
MA1-37166 was used in western blot to study the mechanism by which the MyoD regulates myoblast apoptosis
|Hirai H,Verma M,Watanabe S,Tastad C,Asakura Y,Asakura A||The Journal of cell biology (191:347)||2010|